Matt O'Brien
Stock Analyst at Piper Sandler
(2.27)
# 1,219
Out of 4,650 analysts
162
Total ratings
42.86%
Success rate
-3.76%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMDX TransMedics Group | Reiterates: Overweight | $180 | $88.50 | +103.39% | 7 | Oct 29, 2024 | |
| ITGR Integer Holdings | Reiterates: Overweight | $125 → $140 | $130.10 | +7.61% | 2 | Oct 25, 2024 | |
| PEN Penumbra | Reiterates: Overweight | $200 → $225 | $209.63 | +7.33% | 10 | Oct 18, 2024 | |
| PRCT PROCEPT BioRobotics | Reiterates: Overweight | $75 | $96.69 | -22.43% | 3 | Oct 8, 2024 | |
| PODD Insulet | Maintains: Overweight | $230 → $285 | $232.37 | +22.65% | 7 | Sep 17, 2024 | |
| SYK Stryker | Maintains: Overweight | $380 | $359.01 | +5.85% | 11 | Sep 10, 2024 | |
| DXCM DexCom | Reiterates: Overweight | $90 | $72.24 | +24.58% | 10 | Aug 26, 2024 | |
| MDT Medtronic | Maintains: Neutral | $85 → $90 | $90.32 | -0.35% | 9 | Aug 21, 2024 | |
| TELA TELA Bio | Maintains: Overweight | $10 → $8 | $2.87 | +178.75% | 4 | Aug 13, 2024 | |
| CUTR Cutera | Reiterates: Neutral | $3 → $1 | $0.67 | +49.84% | 12 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $12 | $5.19 | +131.21% | 4 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 → $55 | $32.93 | +67.02% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $12 | $5.42 | +121.40% | 1 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $140 | $137.75 | +1.63% | 8 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $80 | $64.68 | +23.69% | 12 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $40 | $29.43 | +35.92% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $13 | $10.74 | +21.04% | 6 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $205 → $245 | $236.44 | +3.62% | 4 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $80 | $74.29 | +7.69% | 10 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $21 → $9 | $10.33 | -12.88% | 6 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $40 | $30.29 | +32.06% | 6 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 → $6 | $5.27 | +13.85% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $13.11 | +90.69% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $40 | $26.59 | +50.43% | 1 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $5.32 | -43.61% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $1.25 | +260.00% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $62 | $84.56 | -26.68% | 2 | Jul 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $103.88 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $6.13 | +144.70% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $104.53 | +4.04% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $8.92 | +103.81% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $35.99 | +122.28% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $2.56 | +368.75% | 1 | Jun 24, 2020 |
TransMedics Group
Oct 29, 2024
Reiterates: Overweight
Price Target: $180
Current: $88.50
Upside: +103.39%
Integer Holdings
Oct 25, 2024
Reiterates: Overweight
Price Target: $125 → $140
Current: $130.10
Upside: +7.61%
Penumbra
Oct 18, 2024
Reiterates: Overweight
Price Target: $200 → $225
Current: $209.63
Upside: +7.33%
PROCEPT BioRobotics
Oct 8, 2024
Reiterates: Overweight
Price Target: $75
Current: $96.69
Upside: -22.43%
Insulet
Sep 17, 2024
Maintains: Overweight
Price Target: $230 → $285
Current: $232.37
Upside: +22.65%
Stryker
Sep 10, 2024
Maintains: Overweight
Price Target: $380
Current: $359.01
Upside: +5.85%
DexCom
Aug 26, 2024
Reiterates: Overweight
Price Target: $90
Current: $72.24
Upside: +24.58%
Medtronic
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $90.32
Upside: -0.35%
TELA Bio
Aug 13, 2024
Maintains: Overweight
Price Target: $10 → $8
Current: $2.87
Upside: +178.75%
Cutera
Aug 9, 2024
Reiterates: Neutral
Price Target: $3 → $1
Current: $0.67
Upside: +49.84%
Aug 9, 2024
Reiterates: Overweight
Price Target: $15 → $12
Current: $5.19
Upside: +131.21%
Aug 2, 2024
Reiterates: Overweight
Price Target: $50 → $55
Current: $32.93
Upside: +67.02%
Aug 1, 2024
Maintains: Overweight
Price Target: $17 → $12
Current: $5.42
Upside: +121.40%
Aug 1, 2024
Maintains: Overweight
Price Target: $110 → $140
Current: $137.75
Upside: +1.63%
Aug 1, 2024
Maintains: Overweight
Price Target: $95 → $80
Current: $64.68
Upside: +23.69%
Jul 31, 2024
Maintains: Overweight
Price Target: $65 → $40
Current: $29.43
Upside: +35.92%
Jul 30, 2024
Maintains: Overweight
Price Target: $15 → $13
Current: $10.74
Upside: +21.04%
Jul 1, 2024
Upgrades: Overweight
Price Target: $205 → $245
Current: $236.44
Upside: +3.62%
May 20, 2024
Upgrades: Overweight
Price Target: $60 → $80
Current: $74.29
Upside: +7.69%
May 14, 2024
Downgrades: Neutral
Price Target: $21 → $9
Current: $10.33
Upside: -12.88%
May 8, 2024
Maintains: Neutral
Price Target: $33 → $40
Current: $30.29
Upside: +32.06%
May 3, 2024
Reiterates: Neutral
Price Target: $5 → $6
Current: $5.27
Upside: +13.85%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $13.11
Upside: +90.69%
Mar 27, 2024
Reiterates: Overweight
Price Target: $40
Current: $26.59
Upside: +50.43%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $5.32
Upside: -43.61%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $1.25
Upside: +260.00%
Jul 6, 2023
Maintains: Overweight
Price Target: $58 → $62
Current: $84.56
Upside: -26.68%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $103.88
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $6.13
Upside: +144.70%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $104.53
Upside: +4.04%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $8.92
Upside: +103.81%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $35.99
Upside: +122.28%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $2.56
Upside: +368.75%